Email Updates

You are here

Home

5 NOVEMBER 2021 VOLUME 23 ISSUE 44

Media Coverage

  • For Long-Term PrEP, We Need Better Definitions of Adherence, Conference Hears

    No one is in any doubt as to the efficacy of HIV pre-exposure prophylaxis, at least for gay men, the 18th European AIDS Conference (EACS 2021) was told last week. However, the conference heard, we need better tools to monitor its long-term use by individuals and whether they are using it optimally. And PrEP is still nowhere nearly available enough in the parts of Europe that need it most.

    November 5, 2021
    PrEP
    aidsmap

  • Clinics Will Need New Systems To Administer Injectable HIV Therapies, Says Canadian Early Adopter

    Dr. Jonathan Angel, an HIV physician and researcher at the University Hospital of Ottawa in Canada, is one of the first doctors in the world to prescribe the injectable formulation of the drugs cabotegravir and rilpivirine, not as part of as clinical trial, but in standard medical practice.

    November 5, 2021
    Treatment
    aidsmap

  • COVID-19 Pandemic Could Lead to HIV Surge in West & Central Africa, Says UNAIDS Chief

    West and Central Africa could see a rise in HIV infections and AIDS-related deaths in a few years due to disruptions in health services because of the coronavirus pandemic, the executive director of the UN AIDS agency said. Although human immunodeficiency virus (HIV) infection rates, and acquired immunodeficiency syndrome (AIDS)-related deaths have been on a steady decline over the past decade, the region accounted for 22 percent of AIDS-related deaths in 2020.

    November 4, 2021
    General
    Reuters

  • Intersecting Stigma: Rural America, HIV PrEP, and Injection Drug Use

    Despite the lifesaving potential of HIV pre-exposure prophylaxis (PrEP), only 1-2 percent of people who inject drugs (PWID) use it. The intensely negative stigma surrounding both HIV and injection drug use may be preventing people at high risk for HIV from using PrEP. However, this becomes even more disparate in rural areas, where PWID have little to no knowledge of PrEP and PrEP prescribers are significantly more biased against PWID.

    November 2, 2021
    PrEP
    Contagion Live

  • Nurses Can Play a Bigger Role in Helping People With HIV Who Suffer From Mental Illnesses

    Studies show that people living with HIV are often at a higher risk of depression and anxiety, as well as suicide. Spotlight spoke to mental health practitioners, activists and people living with HIV to unpack the link between HIV and mental health.

    November 2, 2021
    Treatment
    Daily Maverick

  • Syphilis Is Resurging in the US, a Sign of Public Health’s Funding Crisis

    When Mai Yang is looking for a patient, she travels light. She dresses deliberately — not too formal, so she won't be mistaken for a police officer; not too casual, so people will look past her tiny 4-foot-10 stature and youthful face and trust her with sensitive health information. Always, she wears closed-toed shoes, "just in case I need to run."

    November 1, 2021
    General
    NPR

  • Advocates Challenge the CDC’s New Effort to Track HIV Spread

    In 2019, one of America’s top public health officials went on the road, promoting an ambitious plan to slash new HIV infections by 90 percent by 2030. “We are now on the verge of bringing an end to the AIDS epidemic as we know it in the United States,” Robert Redfield, then-director of the Centers for Disease Control and Prevention, told a Texas audience that July.

    November 1, 2021
    General
    UNDARK

  • Long-Acting HIV ART: Lessons From a Year of Cabenuva

    One year into offering the first long-acting injectable HIV treatment to his patients, Jonathan Angel, MD, head of the Division of Infectious Diseases at the University of Ottawa, Ontario, Canada, reported that 15 of the 21 of patients who started on the regimen are still taking it, all with viral suppression. Those who weren't cited a combination of inconvenience, injection site pain, and "injection fatigue."

    October 31, 2021
    Treatment
    Medscape

  • Half of Swiss Mothers With HIV Decide To Breastfeed Their Baby When Given the Choice

    For new mothers with HIV, whether to breastfeed their baby has been a difficult choice. Unlike transmission through sex, viral suppression through antiretroviral therapy (ART) may not completely remove the risk of transmission. One of the largest studies, from sub-Saharan Africa, found 0.6 percent of babies born to 1220 mothers who were taking ART became HIV positive themselves within 12 months. But that study did not monitor maternal viral loads.

    October 31, 2021
    Treatment
    aidsmap

  • Without PrEP, a Third of New HIV Cases Occur in MSM at Low Risk

    Nearly one in three gay and bisexual men who were diagnosed with HIV at UK sexual health clinics didn't meet the criteria for "high risk" that would signal to a clinician that they would be good candidates for pre-exposure prophylaxis (PrEP). And that means that people who appear lower risk may still be good candidates for the HIV prevention pills, said Ann Sullivan, MD, consulting physician at Chelsea and Westminster Hospital in London.

    October 30, 2021
    PrEP
    Medscape

  • What Does the Future of HIV Prevention Look Like?

    Justice in terms of health and healthcare is systemically denied on the basis of race and ethnicity, income, gender, age, ability, orientation — that much is clear. What isn't as widely understood is how tightly health disparities, especially around HIV/ AIDS in the US, are tied to one issue in particular: Housing.

    October 29, 2021
    General
    PAPER

  • White People Who Inject Drugs Took More Risks, but More Black People Got HIV

    Black people who inject drugs had the safest sexual behavior of any of the injection drug users surveyed by the Centers for Disease Control and Prevention (CDC) in 2018—but they still had HIV rates more than twice that of their white peers, according to data published in the CDC’s Morbidity and Mortality Weekly Report.

    October 29, 2021
    General
    POZ

  • Malaysian Gynaecologist Creates ‘World’s First Unisex Condom’

    A Malaysian gynaecologist has created what he says is the world's first unisex condom that can be worn by females or males and is made from a medical grade material usually used as a dressing for injuries and wounds.

    October 28, 2021
    Male and Female Condoms
    Reuters

  • Experimental One-Time ‘Functional Cure’ for HIV Begins Human Trials

    Excision BioTherapeutics can now begin using the gene-editing treatment, called CRISPR, to explore if the process could potentially function as a treatment for HIV. Their treatment, EBT-101, uses CRISPR to cut out several pieces of the HIV genome through a one-time treatment.

    October 28, 2021
    Cure
    PinkNews

  • Two People Suppressed HIV for Years While Pausing Medication

    Two people with HIV who were able to stop taking medication for several years without becoming ill from the virus offer clues for future strategies to suppress the infection. But both eventually had to restart taking medication, showing the current limitations of such approaches, says Tae-Wook Chun of the National Institutes of Health (NIH) in Maryland. People with HIV can avoid becoming ill by taking lifelong medicines that stop the virus from multiplying, but copies of the virus remain in their immune memory cells throughout the body.

    October 28, 2021
    Treatment
    NewScientist

  • Give Dapivirine Ring for Free

    In January, the World Health Organization (WHO) recommended the use of the dapivirine ring as an additional HIV prevention choice for women. The female-initiated ring is the first long-acting anti-HIV product and reduces the risk by 35 percent. It is recommended for use during vaginal sex by women over 18 years of age.

    October 22, 2021
    Microbicides
    Nation

Published Research

Announcements